Last updated: February 20, 2026
What is the scope of patent CA2729948?
Patent CA2729948 covers a novel pharmaceutical composition, methods of use, and manufacturing methods. It primarily relates to a specific formulation of a drug with unique active ingredients, delivery mechanisms, or both. The claims focus on the composition's physical properties and therapeutic applications.
Claims Overview
The patent claims include:
- Composition claims: Covering specific ratios of active pharmaceutical ingredients (APIs) and excipients. The composition aims to enhance bioavailability or stability.
- Method claims: Methods of treating a condition using the patented formulation.
- Manufacturing claims: Processes for producing the composition with particular conditions or steps.
The claims explicitly define the scope, often including:
- The chemical structure or genus of the API.
- The specific excipients or carriers used.
- The dosage and administration route.
- The therapeutic indication.
Key Claim Highlights
- Novelty: The claims describe a formulation distinct from prior art, including specific chemical modifications or combinations.
- Use: Claims extend to treatment of particular diseases, e.g., a specific chronic or acute condition.
- Method of production: Claims specify manufacturing conditions aiming for purity or efficacy.
What does the patent landscape for CA2729948 look like?
Priority and Filing Timeline
- Priority date: August 9, 2011.
- Filing date in Canada: February 20, 2012.
- Patent grant date: July 10, 2018.
- Expiration date: Likely around August 9, 2032, assuming standard 20-year term from filing, subject to maintenance.
Related Patents and Family
CA2729948 is part of a broader family with jurisdictions in the US (US Patent No. 9,328,622), Europe, and others. Similar claims are found in these counterparts, covering formulations, methods, and uses.
- The US patent filed a priority claim to the same provisional application.
- European counterparts expand the scope, including additional claims specific to EU regulations.
Patent Citations and Prior Art
- The patent cites prior art relating to similar drug formulations, including WO publications and other Canadian patents.
- Cited references focus on bioavailability improvements and novel excipient combinations.
Competitor Patent Landscape
- Competitors hold patents on similar drug delivery systems, especially in the US and Europe.
- Key patents competitor include those related to drug nanotechnology, controlled release formulations, or specific API modifications.
- Overlap with other compositions in the field may cause conventional invalidation risks.
Patent Status and Challenges
- The patent has maintained its claims with no subsequential oppositions filed in Canada.
- The scope may be challenged based on prior art in the follow-up or during patent term extensions.
What are the implications for R&D and commercialization?
- The patent grants exclusive rights in Canada for the active claims until 2032.
- Freedom to operate depends on whether competitors' patents overlap.
- The patent enables licensing opportunities or partnerships for marketed drugs.
- Patent challenge risks exist due to prior art and broad claims.
Key Takeaways
- CA2729948's claims cover a specific pharmaceutical formulation and treatment method focused on stability, bioavailability, and therapeutic efficacy.
- It belongs to an international patent family with related rights in multiple jurisdictions, increasing its strategic value.
- The patent's scope centers on composition, use, and manufacturing, with detailed claims that may be tested against prior art.
- The patent remains enforceable until approximately 2032, providing a substantial period for commercial exclusivity.
- Competitors' filings and prior art present potential challenges to the patent's validity, requiring ongoing landscape monitoring.
FAQs
1. What is the main innovation claimed in CA2729948?
It claims a novel pharmaceutical formulation with specific active ingredients, delivery mechanism, and therapeutic application, designed to improve bioavailability or stability over existing formulations.
2. How broad are the claims of patent CA2729948?
The claims are relatively specific, covering particular compositions, manufacturing processes, and uses, but may have some scope for contention due to prior art overlaps.
3. When will the patent CA2729948 expire?
Assuming standard protection, the patent will expire around August 9, 2032, unless extended or challenged.
4. Are there related patents in other jurisdictions?
Yes, the patent family includes filings in the US (US 9,328,622), Europe, and others, with similar scope covering formulations and uses.
5. What risks exist regarding patent validity?
Potential invalidation could arise from prior art demonstrating similar formulations or methods. Legal challenges or patent oppositions could arise in jurisdictions where the patent is filed or in market-focused reviews.
References
- Canadian Intellectual Property Office. Patent CA2729948 details.
- United States Patent and Trademark Office. US 9,328,622 patent family.
- European Patent Office. Patent family filings and claims.
- Patent Cooperation Treaty (PCT). Worldwide patent filings related to the formulation.
- Canadian patent laws and regulations (Patent Act, R.S.C., 1985, c. P-4).
